<DOC>
	<DOCNO>NCT01756547</DOCNO>
	<brief_summary>Study assess efficacy safety oral potassium citrate Prevention nephrocalcinosis extreme premature : clinical trial , randomize , double-blind placebo control trial .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Oral Potassium Citrate Prevention Nephrocalcinosis Extreme Premature</brief_title>
	<detailed_description />
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Nephrocalcinosis</mesh_term>
	<mesh_term>Potassium Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Premature infant sex born Hospital Clinic Barcelona . 2 . Corrected gestational age 32 week low birth weight 1500gr . 3 . Survivors 7 day old . 4 . Clinically stable , opinion investigator , time inclusion . 5 . That , properly inform , parent / legal guardian give write consent allow participation infant study submit test examination entail 1 . Renal malformation , cardiac gastrointestinal prenatal postnatal diagnosis . 2 . Chronic renal failure ( serum creatinine &gt; 1.5 mg / dL increase 0.3 mg / dL / day / oliguria define diuresis &lt; 0.5 mL / kg / hour first day life ) 3 . Treatment furosemide dexamethasone 4 . Addison 's disease . 5 . Persistent severe metabolic alkalosis . 6 . Impossibility oral feeding .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Nephrocalcinosis</keyword>
	<keyword>Extreme premature</keyword>
</DOC>